SCHOTT Poonawalla Begins Work on $400 Million India IPO Backed by SCHOTT Pharma and TPG Growth

Key Takeaways

• Proposed $400 million IPO: SCHOTT Poonawalla has started preliminary work on an Indian stock-market listing.
• Investment banks invited: The company has reportedly invited banks to pitch for roles in the proposed offering.
• Global and private equity backing: Germany’s SCHOTT Pharma owns 50% of the business, while TPG Growth holds 35%.
• Serum Institute remains invested: Adar Poonawalla-led Serum Institute of India retains a minority stake and could consider a partial exit through an offer for sale.
• Pharmaceutical packaging focus: The company manufactures vials, ampoules, cartridges and prefillable syringes used in pharmaceutical and biotechnology applications.
• IPO details remain unconfirmed: The proposed issue size, valuation, structure and timetable have not been finalised.

SCHOTT Poonawalla Starts Preparations for an IPO

SCHOTT Poonawalla has begun exploring a public listing in India as companies backed by international businesses and private equity investors increasingly consider the domestic capital market for fundraising and shareholder liquidity.

According to Moneycontrol, the company has invited investment banks to make presentations for the proposed IPO. People familiar with the matter said the offering could target approximately $400 million, although the amount remains provisional.

An IPO allows a company to offer shares to public investors and list its equity on a stock exchange. Depending on the structure, the transaction can raise fresh capital for the business, allow existing shareholders to sell part of their holdings, or achieve both objectives.

SCHOTT Poonawalla’s proposed offering could include a combination of a fresh issue and an offer for sale. A fresh issue would bring money into the company, potentially supporting expansion and other corporate needs. An offer for sale would allow existing investors to sell shares and receive the proceeds themselves.

The precise balance between the two components has not been disclosed. Nor has the company confirmed a final valuation, price range or listing date.

The proposal should therefore be treated as an early-stage IPO plan rather than a confirmed public offering.

Who Owns SCHOTT Poonawalla?

SCHOTT Poonawalla has a shareholder structure that brings together international pharmaceutical packaging expertise, private equity capital and Indian healthcare-sector investment.

Following a transaction announced in May 2025, the ownership structure became:

Shareholder	Stake
SCHOTT Pharma	50%
TPG Growth	35%
Serum Institute of India	15%

Ownership percentages reflect the structure described following the 2025 transaction; the final IPO structure may differ.

SCHOTT Pharma, headquartered in Germany, specialises in drug containment and delivery systems. Its products are used to store and administer injectable medicines, including treatments that require specialised packaging.

TPG Growth is the growth-investment platform of global alternative asset manager TPG. Its investment in SCHOTT Poonawalla gives it exposure to pharmaceutical packaging and the expansion of healthcare manufacturing in India.

Serum Institute of India, part of the Cyrus Poonawalla Group, is a major vaccine manufacturer. Its investment in SCHOTT Poonawalla connects the packaging business with an established Indian healthcare group.

The proposed IPO could provide an opportunity for existing investors to monetise some of their holdings. Moneycontrol reported that Serum Institute could consider selling part of its stake, but no final decision or transaction size has been announced.

The eventual ownership after listing will depend on the final offer structure, shareholder decisions and investor demand.

What Does SCHOTT Poonawalla Manufacture?

SCHOTT Poonawalla manufactures primary pharmaceutical packaging, which refers to packaging that directly contains a medicine and helps protect it during storage, transportation and use.

Its product portfolio includes:

• Vials: Containers used to store injectable medicines and other pharmaceutical formulations.
• Ampoules: Sealed containers commonly used for single-dose medicines.
• Prefillable syringes: Syringe systems supplied with medication already filled, depending on the product and application.
• Cartridges: Containers used in certain injection pens and auto-injector systems.
• Regulatory services: Support for pharmaceutical and biotechnology companies working through product development and regulatory processes.

These products are important because packaging for injectable medicines must meet demanding quality and safety requirements. Container integrity, material compatibility, sterility and manufacturing consistency can affect a medicine’s quality throughout its lifecycle.

SCHOTT Poonawalla says its products are manufactured using high-quality Type I borosilicate glass, a material widely used for pharmaceutical containers because of its chemical resistance and suitability for many injectable formulations.

The business serves pharmaceutical and biotechnology customers, including companies developing biologic medicines and contract development and manufacturing organisations.

Demand for specialised injectable packaging can be supported by growth in biologic drugs, vaccines, self-administered treatments and complex therapies. However, the company’s actual growth prospects will also depend on manufacturing capacity, customer contracts, product qualification requirements, pricing and competition.

Why Is the Business Attracting Investor Interest?

SCHOTT Poonawalla operates in a specialised segment of the healthcare supply chain. Pharmaceutical packaging may be less visible to consumers than the medicines themselves, but it is essential to the safe storage and administration of many treatments.

Suppliers in this market must meet quality standards and customer requirements that can make switching packaging providers a complex process. Pharmaceutical manufacturers typically need confidence that a container will perform reliably and remain compatible with the drug formulation throughout its intended shelf life.

These requirements can create opportunities for established manufacturers with technical expertise, regulatory knowledge and long-standing customer relationships.

India is also an important pharmaceutical manufacturing base, supplying medicines and vaccines to domestic and international markets. Growth in pharmaceutical production can support demand for packaging components, although demand is not guaranteed to rise uniformly across all product categories.

SCHOTT Pharma has described India as a strategically important manufacturing hub. Its partnership with SCHOTT Poonawalla provides a local production platform linked to the German group’s pharmaceutical packaging capabilities.

For TPG Growth, the investment offers exposure to a specialised healthcare business with potential expansion opportunities. For public-market investors, an IPO could provide access to a company operating in an industrial segment connected to pharmaceutical and biotechnology demand.

Nevertheless, the attractiveness of an IPO will depend on the company’s financial performance, valuation, growth strategy, customer concentration, capital expenditure and the final terms of the offer.

How Much Could SCHOTT Poonawalla Be Worth?

The proposed $400 million fundraising target should not be confused with the company’s valuation.

The IPO amount refers to the potential value of shares offered in the transaction. The company’s equity valuation represents the market value of all its shares and could be significantly different from the amount raised.

Moneycontrol previously reported that SCHOTT Poonawalla had been valued at approximately $800 million in connection with discussions around the 2025 stake sale. That historical figure provides context, but it does not establish the valuation for the proposed IPO.

The final valuation could change based on financial performance, growth expectations, comparable listed companies, investor demand and the proportion of shares being offered.

A meaningful assessment will require details such as revenue, operating profit, net profit, debt, cash flow, capital expenditure and the proposed price-to-earnings or enterprise-value-to-EBITDA multiples.

Until a draft red herring prospectus or other formal offer documents become available, investors should avoid treating any reported valuation or fundraising target as final.

What Would the IPO Mean for Existing Shareholders?

A public listing could provide liquidity to existing investors and establish a market-based valuation for SCHOTT Poonawalla.

For TPG Growth, the IPO could create a route to partially realise its investment, depending on the final offer structure and any applicable lock-in requirements. Serum Institute could also consider selling some shares if the offering includes an offer-for-sale component.

SCHOTT Pharma’s position would be different. As the 50% shareholder, it has a substantial interest in the continued development of the Indian joint venture. A public listing could provide the business with greater visibility and potentially support future fundraising, but it would also bring additional disclosure and public-market obligations.

For the company itself, the benefit of an IPO would depend on how much fresh capital is raised and how the proceeds are used. Money raised through an offer for sale goes to selling shareholders rather than directly to the business.

Investors should therefore examine the use-of-proceeds section of the eventual offer documents to determine whether the transaction is primarily intended to fund growth, repay debt, or provide liquidity to existing shareholders.

The Bigger Picture

SCHOTT Poonawalla’s proposed IPO reflects the interest of international businesses and private equity investors in India’s capital markets. A listing could give public investors access to a specialised pharmaceutical packaging manufacturer connected to global drug-containment expertise and India’s healthcare manufacturing ecosystem.

The opportunity, however, will need to be assessed on the company’s own financials and valuation rather than on the reputation of its shareholders alone. Product quality, customer relationships, capacity expansion, profitability and the allocation of IPO proceeds will be important in determining the investment case.

FAQs

1. How much does SCHOTT Poonawalla plan to raise through its IPO?

The company is reportedly considering an IPO of approximately $400 million. The amount is preliminary and could change depending on market conditions and the final offer structure.

2. Who owns SCHOTT Poonawalla?

Following the 2025 transaction, SCHOTT Pharma holds 50%, TPG Growth holds 35%, and Serum Institute of India retains a 15% minority stake.

3. What products does SCHOTT Poonawalla manufacture?

The company manufactures pharmaceutical packaging products, including vials, ampoules, cartridges and prefillable syringes. It also offers regulatory services for pharmaceutical and biotechnology businesses.

4. Has SCHOTT Poonawalla confirmed its IPO date and valuation?

No final IPO date, price band or valuation has been announced in the cited report. The company has reportedly begun preliminary preparations and invited investment banks to pitch for roles in the offering.

Looking Ahead

The next important milestones will be the appointment of investment banks, clarification of the proposed offer structure and publication of formal IPO documents. These developments should provide more information about the company’s financial performance, valuation, planned use of proceeds and the potential participation of existing shareholders.

Until those details emerge, the proposed $400 million offering remains an early-stage plan. For investors, the key will be to evaluate the eventual offer price against SCHOTT Poonawalla’s earnings, growth opportunities, competitive position and capital requirements rather than relying on the headline fundraising target alone.